Loading...
Loading...
REVBU| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 7.2K |
| Gross Profit | -7.2K |
| Operating Expense | 2,515.2K |
| Operating I/L | -2,522.4K |
| Other Income/Expense | -5,867.4K |
| Interest Income | 0.0K |
| Pretax | -8,389.8K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -8,389.8K |
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in immune system therapeutics and diagnostics. The company's product pipeline includes REVTx-99b, a Phase Ib clinical trial candidate for chronic nasal congestion and allergic rhinitis; REVTx-200, a nonclinical stage intranasal therapy; REVTx-300, a potential therapy for chronic organ diseases; and REVDx-501, a rapid test kit for respiratory viral infections. These products are designed to address unmet medical needs and have the potential to generate revenue through commercialization and sales in the pharmaceutical and diagnostic markets.
